Your place and filters are kept while this page loads.
Research library
Source-reported findings · AI-extracted, pending human review.
Collection scope and interpretation
The studied combination, route, population and limitations are available inside each record. Open them before interpreting results.
This is a bounded collection of currently publishable findings from up to 200 processed papers, not a complete literature search. Bibliographic records without extracted findings remain in the study catalog.
Search and filter recordsCollection coverage and availability
632 current public findings from 168 papers before filters.
Records checked .
Showing 101–120 of 632 matching records. Page 6 of 32.
PMID 41100086 · finding version 1 · paper version 2
PMID 41100086: salt intakeAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for salt intake: no detected difference.
employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype; 3-arm randomized clinical trial. treatment versus app-only. salt intake at 3 months At 3 months.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported a direction only for salt intake: no detected difference.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype; 3-arm randomized clinical trial. treatment versus app-only. salt intake at 3 months At 3 months.
Source
PMID 41100086 · finding version 1
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 1; paper version 2. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: no detected difference.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype
Study design
3-arm randomized clinical trial
Analysis population
itt
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
treatment
Comparator
app-only
Measured outcome
salt intake
Timepoint
3 months At 3 months
Limitations and extraction boundaries
Treatment is the source-defined group receiving a genetic profile and AI-based app with sodium-specific information; control receives no intervention; app-only receives the app without genetic profile or information. These exact allocation definitions are retained as source anchors.
Authors report no significant difference at 3 months. This is not equivalence or proof of no effect. No numerical estimate is derived or pooled.
Salt intake was estimated using spot urine and the INTERSALT formula, not measured by a 24-hour urine collection.
312 participants were randomized and 289 completed follow-up; arm-specific outcome analyzed denominators are not provided in this abstract.
Other arm contrasts and secondary outcomes remain unrepresented; these two primary-outcome contrasts share participants and must not be treated as independent studies.
Authors state that analysis was performed on an intention-to-treat basis; additional adjustment is not established by this abstract.
You can stop here, or inspect the evidence and its original sources.
employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype; 3-arm randomized clinical trial. treatment versus app-only. salt intake at 3 months At 3 months.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 41100086: salt intake
Stable finding ID: finding:consumer1000:41100086:2. Finding version: 1. Revision: finding:consumer1000:41100086:2:v1. Content hash: sha256:97ebef11b9a35625fec44ed92af79d5208fbdba75b2a90b43e4d03123827087e.
Paper version: 2. Paper content hash: sha256:627cb26633d8ffb2a133a0969ef5bb0f14965e545a3dba3b16111cb67d91ccf6.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for salt intake: no detected difference.
employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype; 3-arm randomized clinical trial. treatment versus app-only. salt intake at 3 months At 3 months.
Participants / population: employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype.
Study design: 3-arm randomized clinical trial.
Analysis population: itt.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: treatment.
Studied combination: Not encoded in this record.
Studied route / context: Not encoded in this record.
Comparator: app-only.
Measured outcome: salt intake.
Timepoint: 3 months At 3 months.
Source-reported direction: no detected difference. Direction only; no numerical magnitude is available in this record.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Treatment is the source-defined group receiving a genetic profile and AI-based app with sodium-specific information; control receives no intervention; app-only receives the app without genetic profile or information. These exact allocation definitions are retained as source anchors.
Reported limitation: Authors report no significant difference at 3 months. This is not equivalence or proof of no effect. No numerical estimate is derived or pooled.
Reported limitation: Salt intake was estimated using spot urine and the INTERSALT formula, not measured by a 24-hour urine collection.
Reported limitation: 312 participants were randomized and 289 completed follow-up; arm-specific outcome analyzed denominators are not provided in this abstract.
Reported limitation: Other arm contrasts and secondary outcomes remain unrepresented; these two primary-outcome contrasts share participants and must not be treated as independent studies.
Reported limitation: Authors state that analysis was performed on an intention-to-treat basis; additional adjustment is not established by this abstract.
Finding revision: finding:consumer1000:41100086:2:v1.
Finding version: 1.
Finding content hash: sha256:97ebef11b9a35625fec44ed92af79d5208fbdba75b2a90b43e4d03123827087e.
Paper version: 2.
Paper version content hash: sha256:627cb26633d8ffb2a133a0969ef5bb0f14965e545a3dba3b16111cb67d91ccf6.
Source content hash: sha256:3575ad8cdc97a37c47fc1454d3ad6e60631ca1e1556c432cded96ed1024b56aa.
Extraction policy: consumer1000-source-authored:903adc4318bce1000b9927fb3f4401936b709e9f5eab73f759b74e9e3a46e5dd.
Extraction policy hash: sha256:903adc4318bce1000b9927fb3f4401936b709e9f5eab73f759b74e9e3a46e5dd.
Extraction method version: bounded-source-authored-extraction/v2-analysis-population-aliases.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 1767-1869; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 1886-2177; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 1886-2177; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 1641-1672; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 1117-1128; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 2575-2602; applicability.analysisPopulation → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 2508-2562; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 2742-3002; sourceCoverage.armDefinitions → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 1886-2177; sourceCoverage.outcomeMeasurement → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text: PubMed abstract, PMID 41100086, UTF-16 2206-2377.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=41100086&rettype=abstract&retmode=text. Source hash: sha256:3575ad8cdc97a37c47fc1454d3ad6e60631ca1e1556c432cded96ed1024b56aa. Locators: applicability.population: PubMed abstract, PMID 41100086, UTF-16 1767-1869; applicability.experimentalIntervention: PubMed abstract, PMID 41100086, UTF-16 1886-2177; applicability.comparator: PubMed abstract, PMID 41100086, UTF-16 1886-2177; applicability.design: PubMed abstract, PMID 41100086, UTF-16 1641-1672; applicability.outcomeConstruct: PubMed abstract, PMID 41100086, UTF-16 1117-1128; applicability.participantMetric: PubMed abstract, PMID 41100086, UTF-16 2575-2602; applicability.analysisPopulation: PubMed abstract, PMID 41100086, UTF-16 2508-2562; reportedDirection: PubMed abstract, PMID 41100086, UTF-16 2742-3002; sourceCoverage.armDefinitions: PubMed abstract, PMID 41100086, UTF-16 1886-2177; sourceCoverage.outcomeMeasurement: PubMed abstract, PMID 41100086, UTF-16 2206-2377; applicability.timepoint.evidence: PubMed abstract, PMID 41100086, UTF-16 2742-3002.
Canonical paper: /studies/41100086. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 42273789 · finding version 1 · paper version 3
PMID 42273789: CPQ11-14AI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported total CPQ scores (CPQ11-14) as intervention group 8.5 CPQ score and control group 6.9 CPQ score, each summarised separately.
Reported p = 0.218.
bilateral congenitally missing second mandibular premolars; split-mouth study. extraction or hemisection versus age- and gender-matched control group without dental agenesis. total CPQ scores (CPQ11-14) at 4 year 4-year follow-up.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported total CPQ scores (CPQ11-14) as intervention group 8.5 CPQ score and control group 6.9 CPQ score, each summarised separately.
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
bilateral congenitally missing second mandibular premolars; split-mouth study. extraction or hemisection versus age- and gender-matched control group without dental agenesis. total CPQ scores (CPQ11-14) at 4 year 4-year follow-up.
Source
PMID 42273789 · finding version 1
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 1; paper version 3. Exact identity, status and limitations remain in this article.
Reported arm summaries
Values as reported by the source. Dispersion is the type the source recorded.
Study arm
Reported value
Dispersion
Participants
intervention group
8.5 CPQ score
SD 5.6
n=not reported
control group
6.9 CPQ score
SD 5.6
n=not reported
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
bilateral congenitally missing second mandibular premolars
Study design
split-mouth study
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
extraction or hemisection
Comparator
age- and gender-matched control group without dental agenesis
Measured outcome
total CPQ scores (CPQ11-14)
Timepoint
4 year 4-year follow-up
Limitations and extraction boundaries
Design context for this outcome: the total-CPQ result is a matched-cohort comparison within a split-mouth study. The authors state there was no significant difference between the intervention cohort and the age- and gender-matched control cohort at the 4-year follow-up (P = 0.218). The finding records the reported group means and SDs; it does not calculate a between-group effect or establish equivalence.
The study randomized mandibular sides to extraction or hemisection within the intervention participants with bilateral agenesis; the matched control participants did not have dental agenesis. The reported intervention-versus-control comparison is a whole-cohort comparison, not a randomized between-person extraction-versus-control contrast and does not isolate the extraction procedure from hemisection.
The source reports 40 participants in each included cohort, but the abstract does not state the analyzed denominators for the total-CPQ outcome. Arm-level analyzed sample sizes are therefore omitted; analysis population remains unclear.
The abstract also reports higher emotional and social well-being scores in the intervention group, hemisection recalled as more painful than extraction, and post-treatment satisfaction/residual-space results. Those outcomes are not represented by this single total-CPQ summary.
Abstract-only, local machine draft. Rights, family, and extraction-policy authorities remain pending root rebind; no human review is claimed.
You can stop here, or inspect the evidence and its original sources.
bilateral congenitally missing second mandibular premolars; split-mouth study. extraction or hemisection versus age- and gender-matched control group without dental agenesis. total CPQ scores (CPQ11-14) at 4 year 4-year follow-up.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 42273789: CPQ11-14
Stable finding ID: finding:consumer1000:42273789:1. Finding version: 1. Revision: finding:consumer1000:42273789:1:v1. Content hash: sha256:eb146be413b2d9cc253d38dd20b4d5c71a9d5591c41465390bde5961f4c9c2c4.
Paper version: 3. Paper content hash: sha256:151547747a8f6cd8c4f5cf8ee9138ff551cb1ee2764970d9823b9d78b2d06768.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported total CPQ scores (CPQ11-14) as intervention group 8.5 CPQ score and control group 6.9 CPQ score, each summarised separately.
bilateral congenitally missing second mandibular premolars; split-mouth study. extraction or hemisection versus age- and gender-matched control group without dental agenesis. total CPQ scores (CPQ11-14) at 4 year 4-year follow-up.
Participants / population: bilateral congenitally missing second mandibular premolars.
Study design: split-mouth study.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: extraction or hemisection.
Studied combination: Not encoded in this record.
Studied route / context: Not encoded in this record.
Comparator: age- and gender-matched control group without dental agenesis.
Measured outcome: total CPQ scores (CPQ11-14).
Timepoint: 4 year 4-year follow-up.
intervention group: reported value 8.5 CPQ score; SD 5.6; participants not reported.
control group: reported value 6.9 CPQ score; SD 5.6; participants not reported.
Reported p = 0.218.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Design context for this outcome: the total-CPQ result is a matched-cohort comparison within a split-mouth study. The authors state there was no significant difference between the intervention cohort and the age- and gender-matched control cohort at the 4-year follow-up (P = 0.218). The finding records the reported group means and SDs; it does not calculate a between-group effect or establish equivalence.
Reported limitation: The study randomized mandibular sides to extraction or hemisection within the intervention participants with bilateral agenesis; the matched control participants did not have dental agenesis. The reported intervention-versus-control comparison is a whole-cohort comparison, not a randomized between-person extraction-versus-control contrast and does not isolate the extraction procedure from hemisection.
Reported limitation: The source reports 40 participants in each included cohort, but the abstract does not state the analyzed denominators for the total-CPQ outcome. Arm-level analyzed sample sizes are therefore omitted; analysis population remains unclear.
Reported limitation: The abstract also reports higher emotional and social well-being scores in the intervention group, hemisection recalled as more painful than extraction, and post-treatment satisfaction/residual-space results. Those outcomes are not represented by this single total-CPQ summary.
Reported limitation: Abstract-only, local machine draft. Rights, family, and extraction-policy authorities remain pending root rebind; no human review is claimed.
Finding revision: finding:consumer1000:42273789:1:v1.
Finding version: 1.
Finding content hash: sha256:eb146be413b2d9cc253d38dd20b4d5c71a9d5591c41465390bde5961f4c9c2c4.
Paper version: 3.
Paper version content hash: sha256:151547747a8f6cd8c4f5cf8ee9138ff551cb1ee2764970d9823b9d78b2d06768.
Source content hash: sha256:c53998343fe6e3a501490dba9d40ad28d15ef09bf1970cdff09f088f7285e84a.
Extraction policy: consumer1000-source-authored:d5d362be43c3da0376972267efb0a80138680c52893628959732581ca3bfa514.
Extraction policy hash: sha256:d5d362be43c3da0376972267efb0a80138680c52893628959732581ca3bfa514.
Extraction method version: bounded-source-authored-extraction/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1288-1452; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1453-1525; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1057-1213; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1222-1278; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; applicability.instrument → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1526-1814; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1824-1943; applicability.timepoint.evidence → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1526-1549; experimental.armLabel → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; experimental.unit → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; experimental.mean → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; experimental.dispersion.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; comparator.armLabel → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; comparator.unit → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; comparator.mean → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; comparator.dispersion.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151; reportedSignificance.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text: PubMed metadata abstract UTF-16 1944-2151.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42273789&rettype=abstract&retmode=text. Source hash: sha256:c53998343fe6e3a501490dba9d40ad28d15ef09bf1970cdff09f088f7285e84a. Locators: applicability.population: PubMed metadata abstract UTF-16 1288-1452; applicability.experimentalIntervention: PubMed metadata abstract UTF-16 1453-1525; applicability.comparator: PubMed metadata abstract UTF-16 1057-1213; applicability.design: PubMed metadata abstract UTF-16 1222-1278; applicability.outcomeConstruct: PubMed metadata abstract UTF-16 1944-2151; applicability.instrument: PubMed metadata abstract UTF-16 1526-1814; applicability.participantMetric: PubMed metadata abstract UTF-16 1824-1943; applicability.timepoint.evidence: PubMed metadata abstract UTF-16 1526-1549; experimental.armLabel: PubMed metadata abstract UTF-16 1944-2151; experimental.unit: PubMed metadata abstract UTF-16 1944-2151; experimental.mean: PubMed metadata abstract UTF-16 1944-2151; experimental.dispersion.value: PubMed metadata abstract UTF-16 1944-2151; comparator.armLabel: PubMed metadata abstract UTF-16 1944-2151; comparator.unit: PubMed metadata abstract UTF-16 1944-2151; comparator.mean: PubMed metadata abstract UTF-16 1944-2151; comparator.dispersion.value: PubMed metadata abstract UTF-16 1944-2151; reportedSignificance.value: PubMed metadata abstract UTF-16 1944-2151; applicability.timepoint.evidence: PubMed metadata abstract UTF-16 1526-1549.
Canonical paper: /studies/42273789. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39252819 · finding version 2 · paper version 4
PMID 39252819: Oura ringAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) remains unresolved in this record.
Reported p < 0.05.
Studied combination: MgT.
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) at 21 days MgT or placebo.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Direction for deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) remains unresolved in this record.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) at 21 days MgT or placebo.
Source
PMID 39252819 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 4. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: unclear.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
Eighty 35-55-year-olds with self-assessed sleep problems
Study design
randomized, double-blind, placebo-controlled, parallel-arm study
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
1 g/day of MgT
Studied combination
MgT
Comparator
placebo
Measured outcome
deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring)
Timepoint
21 days MgT or placebo
Limitations and extraction boundaries
The abstract reports bundled outcomes without endpoint-specific effect sizes, confidence intervals, or arm-level means/SDs.
The abstract reports 80 participants but does not state allocation counts by arm.
The abstract lists standardized questionnaires including the Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, and Restorative Sleep Questionnaire; it does not map each listed symptom result to a specific questionnaire.
The result sentence explicitly says MgT significantly improved vs placebo, but the current direction-source guard does not accept this “improved vs” phrase form; direction remains unclear pending source-matched guard support. No inferential direction is invented.
“Safe and well tolerated” appears in the abstract without adverse-event counts; this is not a safety guarantee.
You can stop here, or inspect the evidence and its original sources.
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) at 21 days MgT or placebo.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 39252819: Oura ring
Stable finding ID: finding:examine2025:39252819:1. Finding version: 2. Revision: finding:examine2025:39252819:1:v2. Content hash: sha256:088854b4ade679b9607bb5fc66922f3f5b0c6f5d315731d6b8f1b15e8d4e54cd.
Paper version: 4. Paper content hash: sha256:7fbd5839c1b53e9a756560cefbd8c7b00ccda6f69b623a9a992f9a061be6f70c.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) remains unresolved in this record.
Studied combination: MgT.
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring) at 21 days MgT or placebo.
Participants / population: Eighty 35-55-year-olds with self-assessed sleep problems.
Study design: randomized, double-blind, placebo-controlled, parallel-arm study.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: 1 g/day of MgT.
Studied combination: MgT.
Studied route / context: Not encoded in this record.
Comparator: placebo.
Measured outcome: deep sleep score, REM sleep score, light sleep time, and activity and readiness parameters activity score, activity daily movement score, readiness score, readiness activity balance, and readiness sleep balance (Oura ring).
Timepoint: 21 days MgT or placebo.
Source-reported direction: unclear. Direction only; no numerical magnitude is available in this record.
Reported p < 0.05.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: The abstract reports bundled outcomes without endpoint-specific effect sizes, confidence intervals, or arm-level means/SDs.
Reported limitation: The abstract reports 80 participants but does not state allocation counts by arm.
Reported limitation: The abstract lists standardized questionnaires including the Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, and Restorative Sleep Questionnaire; it does not map each listed symptom result to a specific questionnaire.
Reported limitation: The result sentence explicitly says MgT significantly improved vs placebo, but the current direction-source guard does not accept this “improved vs” phrase form; direction remains unclear pending source-matched guard support. No inferential direction is invented.
Reported limitation: “Safe and well tolerated” appears in the abstract without adverse-event counts; this is not a safety guarantee.
Finding revision: finding:examine2025:39252819:1:v2.
Finding version: 2.
Finding content hash: sha256:088854b4ade679b9607bb5fc66922f3f5b0c6f5d315731d6b8f1b15e8d4e54cd.
Paper version: 4.
Paper version content hash: sha256:7fbd5839c1b53e9a756560cefbd8c7b00ccda6f69b623a9a992f9a061be6f70c.
Source content hash: sha256:c4b7769061135e25a2cac2ee4af52513981625fc752a867e9a3cbccb2ca9bec8.
Extraction policy: examine2025-mgt-context-v1:a10d577ec738522e2f61d58c31a77d841f7def8d769405a593e540316bed0601.
Extraction policy hash: sha256:a10d577ec738522e2f61d58c31a77d841f7def8d769405a593e540316bed0601.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, participants; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, arms/dose; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, intervention component; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, comparator; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, design; applicability.instrument → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, measurement method; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, objective outcome bundle; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, participant metric; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, objective source-reported comparison; reportedSignificance.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, objective bundled p threshold; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, exact source context.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text. Source hash: sha256:c4b7769061135e25a2cac2ee4af52513981625fc752a867e9a3cbccb2ca9bec8. Locators: applicability.population: Abstract, Patients/Methods, participants; applicability.experimentalIntervention: Abstract, Patients/Methods, arms/dose; applicability.experimentalInterventionComponents: Abstract, Patients/Methods, intervention component; applicability.comparator: Abstract, Patients/Methods, comparator; applicability.design: Abstract, Patients/Methods, design; applicability.instrument: Abstract, Patients/Methods, measurement method; applicability.outcomeConstruct: Abstract, Results, objective outcome bundle; applicability.participantMetric: Abstract, Patients/Methods, participant metric; reportedDirection: Abstract, Results, objective source-reported comparison; reportedSignificance.value: Abstract, Results, objective bundled p threshold; limitations: Abstract, Results, exact source context; contextMapping.definition: Abstract, definition — provisional related context; contextMapping.methods: Abstract, methods — provisional related context; contextMapping.authorScope: Abstract, authorScope — provisional related context; contextMapping.methods: Abstract, methods — provisional related context; contextMapping.objectiveResult: Abstract, objectiveResult — provisional related context; contextMapping.authorScope: Abstract, authorScope — provisional related context; applicability.timepoint: Abstract, Patients/Methods, 21-day intervention period.
Canonical paper: /studies/39252819. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39252819 · finding version 2 · paper version 4
PMID 39252819: standardized questionnairesAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) remains unresolved in this record.
Reported p < 0.05.
Studied combination: MgT.
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) at 21 days MgT or placebo.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Direction for behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) remains unresolved in this record.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) at 21 days MgT or placebo.
Source
PMID 39252819 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 4. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: unclear.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
Eighty 35-55-year-olds with self-assessed sleep problems
Study design
randomized, double-blind, placebo-controlled, parallel-arm study
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
1 g/day of MgT
Studied combination
MgT
Comparator
placebo
Measured outcome
behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires)
Timepoint
21 days MgT or placebo
Limitations and extraction boundaries
The abstract reports bundled outcomes without endpoint-specific effect sizes, confidence intervals, or arm-level means/SDs.
The abstract reports 80 participants but does not state allocation counts by arm.
The abstract lists standardized questionnaires including the Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, and Restorative Sleep Questionnaire; it does not map each listed symptom result to a specific questionnaire.
The result sentence explicitly says MgT significantly improved vs placebo, but the current direction-source guard does not accept this “improved vs” phrase form; direction remains unclear pending source-matched guard support. No inferential direction is invented.
“Safe and well tolerated” appears in the abstract without adverse-event counts; this is not a safety guarantee.
You can stop here, or inspect the evidence and its original sources.
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) at 21 days MgT or placebo.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 39252819: standardized questionnaires
Stable finding ID: finding:examine2025:39252819:2. Finding version: 2. Revision: finding:examine2025:39252819:2:v2. Content hash: sha256:ac64c7616a028b73f7e6f24a1e60be2970f89332aae2c3000ca9124708837943.
Paper version: 4. Paper content hash: sha256:7fbd5839c1b53e9a756560cefbd8c7b00ccda6f69b623a9a992f9a061be6f70c.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) remains unresolved in this record.
Studied combination: MgT.
Eighty 35-55-year-olds with self-assessed sleep problems; randomized, double-blind, placebo-controlled, parallel-arm study. 1 g/day of MgT versus placebo. behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires) at 21 days MgT or placebo.
Participants / population: Eighty 35-55-year-olds with self-assessed sleep problems.
Study design: randomized, double-blind, placebo-controlled, parallel-arm study.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: 1 g/day of MgT.
Studied combination: MgT.
Studied route / context: Not encoded in this record.
Comparator: placebo.
Measured outcome: behavior upon awakening, energy and daytime productivity, grouchiness, mood and mental alertness (standardized questionnaires).
Timepoint: 21 days MgT or placebo.
Source-reported direction: unclear. Direction only; no numerical magnitude is available in this record.
Reported p < 0.05.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: The abstract reports bundled outcomes without endpoint-specific effect sizes, confidence intervals, or arm-level means/SDs.
Reported limitation: The abstract reports 80 participants but does not state allocation counts by arm.
Reported limitation: The abstract lists standardized questionnaires including the Insomnia Severity Index, Leeds Sleep Evaluation Questionnaire, and Restorative Sleep Questionnaire; it does not map each listed symptom result to a specific questionnaire.
Reported limitation: The result sentence explicitly says MgT significantly improved vs placebo, but the current direction-source guard does not accept this “improved vs” phrase form; direction remains unclear pending source-matched guard support. No inferential direction is invented.
Reported limitation: “Safe and well tolerated” appears in the abstract without adverse-event counts; this is not a safety guarantee.
Finding revision: finding:examine2025:39252819:2:v2.
Finding version: 2.
Finding content hash: sha256:ac64c7616a028b73f7e6f24a1e60be2970f89332aae2c3000ca9124708837943.
Paper version: 4.
Paper version content hash: sha256:7fbd5839c1b53e9a756560cefbd8c7b00ccda6f69b623a9a992f9a061be6f70c.
Source content hash: sha256:c4b7769061135e25a2cac2ee4af52513981625fc752a867e9a3cbccb2ca9bec8.
Extraction policy: examine2025-mgt-context-v1:a10d577ec738522e2f61d58c31a77d841f7def8d769405a593e540316bed0601.
Extraction policy hash: sha256:a10d577ec738522e2f61d58c31a77d841f7def8d769405a593e540316bed0601.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, participants; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, arms/dose; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, intervention component; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, comparator; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, design; applicability.instrument → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, measurement method; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, subjective outcome bundle; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Patients/Methods, participant metric; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, subjective source-reported comparison; reportedSignificance.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, subjective bundled p threshold; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text: Abstract, Results, exact source context.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39252819&rettype=abstract&retmode=text. Source hash: sha256:c4b7769061135e25a2cac2ee4af52513981625fc752a867e9a3cbccb2ca9bec8. Locators: applicability.population: Abstract, Patients/Methods, participants; applicability.experimentalIntervention: Abstract, Patients/Methods, arms/dose; applicability.experimentalInterventionComponents: Abstract, Patients/Methods, intervention component; applicability.comparator: Abstract, Patients/Methods, comparator; applicability.design: Abstract, Patients/Methods, design; applicability.instrument: Abstract, Patients/Methods, measurement method; applicability.outcomeConstruct: Abstract, Results, subjective outcome bundle; applicability.participantMetric: Abstract, Patients/Methods, participant metric; reportedDirection: Abstract, Results, subjective source-reported comparison; reportedSignificance.value: Abstract, Results, subjective bundled p threshold; limitations: Abstract, Results, exact source context; contextMapping.definition: Abstract, definition — provisional related context; contextMapping.methods: Abstract, methods — provisional related context; contextMapping.authorScope: Abstract, authorScope — provisional related context; applicability.timepoint: Abstract, Patients/Methods, 21-day intervention period.
Canonical paper: /studies/39252819. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39364857 · finding version 2 · paper version 3
Training, detraining and retraining findingsAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Reported arm completers: CRT 22; PRT 20.
randomized parallel training sequences. 55 randomized participants. Analysis population: unclear.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Reported arm completers: CRT 22; PRT 20.
Source statement 1
Reported arm completers: CRT 22; PRT 20.
Source statement 2
leg press one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Source statement 3
leg press one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Source statement 4
biceps curl one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Source statement 5
biceps curl one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Source statement 6
vastus lateralis muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Source statement 7
vastus lateralis muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Source statement 8
biceps brachii muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Source statement 9
biceps brachii muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Source statement 10
countermovement jump height — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Source statement 11
countermovement jump height — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Source statement 12
leg press one repetition maximum — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
Source statement 13
vastus lateralis muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
Source statement 14
biceps brachii muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
randomized parallel training sequences. 55 randomized participants. Analysis population: unclear.
Source
PMID 39364857 · finding version 2
Each record retains its source-reported context and uncertainty.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Exact source-reported statements
randomized parallel training sequences. 55 randomized participants. Analysis population: unclear.
Reported arm completers: CRT 22; PRT 20.
leg press one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
leg press one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
biceps curl one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
biceps curl one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
vastus lateralis muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
vastus lateralis muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
biceps brachii muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
biceps brachii muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
countermovement jump height — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
countermovement jump height — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
leg press one repetition maximum — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
vastus lateralis muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
biceps brachii muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Authors-reported finding
Reported arm completers: CRT 22; PRT 20.
Authors-reported finding
leg press one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Authors-reported finding
leg press one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Authors-reported finding
biceps curl one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Authors-reported finding
biceps curl one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Authors-reported finding
vastus lateralis muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Authors-reported finding
vastus lateralis muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Authors-reported finding
biceps brachii muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Authors-reported finding
biceps brachii muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Authors-reported finding
countermovement jump height — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
Authors-reported finding
countermovement jump height — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
Authors-reported finding
leg press one repetition maximum — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
Authors-reported finding
vastus lateralis muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
Authors-reported finding
biceps brachii muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
Limitations and extraction boundaries
Authors-reported study comparisons and phases; no platform pooling.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Within-arm change during detraining; not a randomized between-group effect.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Within-arm change during detraining; not a randomized between-group effect.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Within-arm change during detraining; not a randomized between-group effect.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Within-arm change during detraining; not a randomized between-group effect.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Within-arm change during detraining; not a randomized between-group effect.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Completer counts are not randomized arm sizes.
No detected difference is not equivalence or noninferiority.
No numerical effect estimate or cross-phase contrast is computed.
Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
You can stop here, or inspect the evidence and its original sources.
Reported arm completers: CRT 22; PRT 20.
leg press one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
leg press one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
biceps curl one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
biceps curl one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
vastus lateralis muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
vastus lateralis muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
biceps brachii muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
biceps brachii muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
countermovement jump height — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference
countermovement jump height — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height)
leg press one repetition maximum — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
vastus lateralis muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
biceps brachii muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area)
randomized parallel training sequences. 55 randomized participants. Analysis population: unclear.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
Training, detraining and retraining findings
Stable finding ID: finding:examine2025:39364857:1. Finding version: 2. Revision: finding:examine2025:39364857:1:v2. Content hash: sha256:6a10c441bd858c17ff9b87c4f4eebc5a0257747201fdd8879be541359878a0f9.
Paper version: 3. Paper content hash: sha256:2bdb127f3ee25c92a6bf1cb57b2a3eaeea3b9dddd26c082f3a18001ee72c7e56.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Reported arm completers: CRT 22; PRT 20.
randomized parallel training sequences. 55 randomized participants. Analysis population: unclear.
Authors-reported finding: Reported arm completers: CRT 22; PRT 20..
Authors-reported finding: leg press one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference.
Authors-reported finding: leg press one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height).
Authors-reported finding: biceps curl one repetition maximum — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference.
Authors-reported finding: biceps curl one repetition maximum — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height).
Authors-reported finding: vastus lateralis muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference.
Authors-reported finding: vastus lateralis muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height).
Authors-reported finding: biceps brachii muscle cross-sectional area — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference.
Authors-reported finding: biceps brachii muscle cross-sectional area — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height).
Authors-reported finding: countermovement jump height — PRT versus CRT; postintervention authors-named postintervention window. No detected between-group difference.
Authors-reported finding: countermovement jump height — Within PRT during the named phase; 10-week detraining period in PRT after the first 10-week resistance-training period. Decrease within the stated arm and phase. Source reported p < 0.05 for the outcome bundle (leg press one repetition maximum, biceps curl one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area, countermovement jump height).
Authors-reported finding: leg press one repetition maximum — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area).
Authors-reported finding: vastus lateralis muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area).
Authors-reported finding: biceps brachii muscle cross-sectional area — PRT versus CRT; first 5 weeks of retraining in PRT start of retraining after detraining. Compared phases: PRT first 5 weeks of retraining in PRT start of retraining after detraining; CRT Weeks 10-15 of CRT authors-named CRT phase. Greater in the stated experimental group at the compared phases. Source reported p < 0.01 for the outcome bundle (leg press one repetition maximum, vastus lateralis muscle cross-sectional area, biceps brachii muscle cross-sectional area).
Each record retains its source-reported context and uncertainty.
Reported limitation: Authors-reported study comparisons and phases; no platform pooling.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Within-arm change during detraining; not a randomized between-group effect.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Within-arm change during detraining; not a randomized between-group effect.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Within-arm change during detraining; not a randomized between-group effect.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Within-arm change during detraining; not a randomized between-group effect.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Within-arm change during detraining; not a randomized between-group effect.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Reported limitation: Completer counts are not randomized arm sizes.
Reported limitation: No detected difference is not equivalence or noninferiority.
Reported limitation: No numerical effect estimate or cross-phase contrast is computed.
Reported limitation: Threshold p values belong to the source-reported outcome bundle, not independently asserted outcome tests.
Reported limitation: The abstract reports no between-group differences and similar postintervention adaptations; no endpoint-specific test or equivalence is inferred.
Finding revision: finding:examine2025:39364857:1:v2.
Finding version: 2.
Finding content hash: sha256:6a10c441bd858c17ff9b87c4f4eebc5a0257747201fdd8879be541359878a0f9.
Paper version: 3.
Paper version content hash: sha256:2bdb127f3ee25c92a6bf1cb57b2a3eaeea3b9dddd26c082f3a18001ee72c7e56.
Source content hash: sha256:c02eb924c0ded4a811423052557666500846d5fc5925ccab4f228919d8a868fb.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: study_comparisons.clause0 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:624-829; study_comparisons.clause1 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:830-914; study_comparisons.clause2 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:915-973; study_comparisons.clause3 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:1034-1326; study_comparisons.clause4 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:1327-1451; study_comparisons.clause5 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:1452-1550; study_comparisons.clause6 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:1551-1705; study_comparisons.clause7 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text: abstract:1706-1866.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39364857&rettype=abstract&retmode=text. Source hash: sha256:c02eb924c0ded4a811423052557666500846d5fc5925ccab4f228919d8a868fb. Locators: study_comparisons.clause0: abstract:624-829; study_comparisons.clause1: abstract:830-914; study_comparisons.clause2: abstract:915-973; study_comparisons.clause3: abstract:1034-1326; study_comparisons.clause4: abstract:1327-1451; study_comparisons.clause5: abstract:1452-1550; study_comparisons.clause6: abstract:1551-1705; study_comparisons.clause7: abstract:1706-1866; study_comparisons.clause0: abstract:624-829; study_comparisons.clause1: abstract:830-914; study_comparisons.clause2: abstract:915-973; study_comparisons.clause3: abstract:1034-1326; study_comparisons.clause4: abstract:1327-1451; study_comparisons.clause5: abstract:1452-1550; study_comparisons.clause6: abstract:1551-1705; study_comparisons.clause7: abstract:1706-1866; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8; study_comparisons.clause0: abstract:624-829; study_comparisons.clause1: abstract:830-914; study_comparisons.clause2: abstract:915-973; study_comparisons.clause3: abstract:1034-1326; study_comparisons.clause4: abstract:1327-1451; study_comparisons.clause5: abstract:1452-1550; study_comparisons.clause6: abstract:1551-1705; study_comparisons.clause7: abstract:1706-1866; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8; study_comparisons.clause0: abstract:624-829; study_comparisons.clause1: abstract:830-914; study_comparisons.clause2: abstract:915-973; study_comparisons.clause3: abstract:1034-1326; study_comparisons.clause4: abstract:1327-1451; study_comparisons.clause5: abstract:1452-1550; study_comparisons.clause6: abstract:1551-1705; study_comparisons.clause7: abstract:1706-1866; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8; study_comparisons.clause0: abstract:624-829; study_comparisons.clause1: abstract:830-914; study_comparisons.clause2: abstract:915-973; study_comparisons.clause3: abstract:1034-1326; study_comparisons.clause4: abstract:1327-1451; study_comparisons.clause5: abstract:1452-1550; study_comparisons.clause6: abstract:1551-1705; study_comparisons.clause7: abstract:1706-1866; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8.
Canonical paper: /studies/39364857. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39427878 · finding version 2 · paper version 3
Four-arm fat-loss comparisonsAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
four arm randomized trial secondary analysis. 82 randomized participants. Population: persons living with type 2 diabetes. Analysis population: unclear. Fields not recorded or incorporated in this summary may still be present in the paper.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
Source statement 1
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
Source statement 2
fat mass percentage — DCON versus CON; 16 weeks randomized allocation. Authors reported MD -3.5 fat-mass percentage points; 95% CI -5.6 to -1.4.
Source statement 3
fat mass percentage — MED versus CON; 16 weeks randomized allocation. Authors reported MD -6.3 fat-mass percentage points; 95% CI -8.4 to -4.1.
Source statement 4
fat mass percentage — HED versus CON; 16 weeks randomized allocation. Authors reported MD -8 fat-mass percentage points; 95% CI -10.2 to -5.8.
Source statement 5
fat mass percentage — MED versus DCON; 16 weeks randomized allocation. Authors reported MD -2.8 fat-mass percentage points; 95% CI -4.9 to -0.7.
Source statement 6
fat mass percentage — HED versus DCON; 16 weeks randomized allocation. Authors reported MD -4.5 fat-mass percentage points; 95% CI -6.6 to -2.4.
Source statement 7
fat mass percentage — HED versus MED; 16 weeks randomized allocation. Authors reported MD -1.8 fat-mass percentage points; 95% CI -3.9 to 0.4.
Source statement 8
visceral adipose tissue volume — DCON versus CON; 16 weeks randomized allocation. Authors reported difference -666 cm³; 95% CI -912.8 to -385.1.
Source statement 9
visceral adipose tissue volume — MED versus CON; 16 weeks randomized allocation. Authors reported difference -1264 cm³; 95% CI -1679.6 to -655.9.
Source statement 10
visceral adipose tissue volume — HED versus CON; 16 weeks randomized allocation. Authors reported difference -1786.4 cm³; 95% CI -2264.6 to -1321.2.
Source statement 11
visceral adipose tissue volume — HED versus DCON; 16 weeks randomized allocation. Authors reported difference -1120.4 cm³; 95% CI -1746.6 to -639.4.
Source statement 12
Additional authors-reported context: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred. Comparison mapping remains unresolved.
Source statement 13
Additional authors-reported context: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review. Comparison mapping remains unresolved.
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
four arm randomized trial secondary analysis. 82 randomized participants. Population: persons living with type 2 diabetes. Analysis population: unclear. Fields not recorded or incorporated in this summary may still be present in the paper.
Source
PMID 39427878 · finding version 2
Each record retains its source-reported context and uncertainty.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Exact source-reported statements
four arm randomized trial secondary analysis. 82 randomized participants. Population: persons living with type 2 diabetes. Analysis population: unclear. Fields not recorded or incorporated in this summary may still be present in the paper.
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
fat mass percentage — DCON versus CON; 16 weeks randomized allocation. Authors reported MD -3.5 fat-mass percentage points; 95% CI -5.6 to -1.4.
fat mass percentage — MED versus CON; 16 weeks randomized allocation. Authors reported MD -6.3 fat-mass percentage points; 95% CI -8.4 to -4.1.
fat mass percentage — HED versus CON; 16 weeks randomized allocation. Authors reported MD -8 fat-mass percentage points; 95% CI -10.2 to -5.8.
fat mass percentage — MED versus DCON; 16 weeks randomized allocation. Authors reported MD -2.8 fat-mass percentage points; 95% CI -4.9 to -0.7.
fat mass percentage — HED versus DCON; 16 weeks randomized allocation. Authors reported MD -4.5 fat-mass percentage points; 95% CI -6.6 to -2.4.
fat mass percentage — HED versus MED; 16 weeks randomized allocation. Authors reported MD -1.8 fat-mass percentage points; 95% CI -3.9 to 0.4.
visceral adipose tissue volume — DCON versus CON; 16 weeks randomized allocation. Authors reported difference -666 cm³; 95% CI -912.8 to -385.1.
visceral adipose tissue volume — MED versus CON; 16 weeks randomized allocation. Authors reported difference -1264 cm³; 95% CI -1679.6 to -655.9.
visceral adipose tissue volume — HED versus CON; 16 weeks randomized allocation. Authors reported difference -1786.4 cm³; 95% CI -2264.6 to -1321.2.
visceral adipose tissue volume — HED versus DCON; 16 weeks randomized allocation. Authors reported difference -1120.4 cm³; 95% CI -1746.6 to -639.4.
Additional authors-reported context: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred. Comparison mapping remains unresolved.
Additional authors-reported context: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review. Comparison mapping remains unresolved.
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Authors-reported finding
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
Authors-reported finding
fat mass percentage — DCON versus CON; 16 weeks randomized allocation. Authors reported MD -3.5 fat-mass percentage points; 95% CI -5.6 to -1.4.
Authors-reported finding
fat mass percentage — MED versus CON; 16 weeks randomized allocation. Authors reported MD -6.3 fat-mass percentage points; 95% CI -8.4 to -4.1.
Authors-reported finding
fat mass percentage — HED versus CON; 16 weeks randomized allocation. Authors reported MD -8 fat-mass percentage points; 95% CI -10.2 to -5.8.
Authors-reported finding
fat mass percentage — MED versus DCON; 16 weeks randomized allocation. Authors reported MD -2.8 fat-mass percentage points; 95% CI -4.9 to -0.7.
Authors-reported finding
fat mass percentage — HED versus DCON; 16 weeks randomized allocation. Authors reported MD -4.5 fat-mass percentage points; 95% CI -6.6 to -2.4.
Authors-reported finding
fat mass percentage — HED versus MED; 16 weeks randomized allocation. Authors reported MD -1.8 fat-mass percentage points; 95% CI -3.9 to 0.4.
Authors-reported finding
visceral adipose tissue volume — DCON versus CON; 16 weeks randomized allocation. Authors reported difference -666 cm³; 95% CI -912.8 to -385.1.
Authors-reported finding
visceral adipose tissue volume — MED versus CON; 16 weeks randomized allocation. Authors reported difference -1264 cm³; 95% CI -1679.6 to -655.9.
Authors-reported finding
visceral adipose tissue volume — HED versus CON; 16 weeks randomized allocation. Authors reported difference -1786.4 cm³; 95% CI -2264.6 to -1321.2.
Authors-reported finding
visceral adipose tissue volume — HED versus DCON; 16 weeks randomized allocation. Authors reported difference -1120.4 cm³; 95% CI -1746.6 to -639.4.
Authors-reported finding
Additional authors-reported context: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred. Comparison mapping remains unresolved.
Authors-reported finding
Additional authors-reported context: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review. Comparison mapping remains unresolved.
Limitations and extraction boundaries
Authors-reported study comparisons and phases; no platform pooling.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Only independently source-stated VAT numeric contrasts are represented.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Only independently source-stated VAT numeric contrasts are represented.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Only independently source-stated VAT numeric contrasts are represented.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Secondary analysis of a four-arm randomized trial.
Adjustment and analysis population are not established by this extraction.
Allocation counts are not analyzed sample sizes.
Authors-reported contrasts; no platform synthesis or component-level attribution.
Only independently source-stated VAT numeric contrasts are represented.
Study population: persons living with type 2 diabetes.
Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
You can stop here, or inspect the evidence and its original sources.
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
fat mass percentage — DCON versus CON; 16 weeks randomized allocation. Authors reported MD -3.5 fat-mass percentage points; 95% CI -5.6 to -1.4.
fat mass percentage — MED versus CON; 16 weeks randomized allocation. Authors reported MD -6.3 fat-mass percentage points; 95% CI -8.4 to -4.1.
fat mass percentage — HED versus CON; 16 weeks randomized allocation. Authors reported MD -8 fat-mass percentage points; 95% CI -10.2 to -5.8.
fat mass percentage — MED versus DCON; 16 weeks randomized allocation. Authors reported MD -2.8 fat-mass percentage points; 95% CI -4.9 to -0.7.
fat mass percentage — HED versus DCON; 16 weeks randomized allocation. Authors reported MD -4.5 fat-mass percentage points; 95% CI -6.6 to -2.4.
fat mass percentage — HED versus MED; 16 weeks randomized allocation. Authors reported MD -1.8 fat-mass percentage points; 95% CI -3.9 to 0.4.
visceral adipose tissue volume — DCON versus CON; 16 weeks randomized allocation. Authors reported difference -666 cm³; 95% CI -912.8 to -385.1.
visceral adipose tissue volume — MED versus CON; 16 weeks randomized allocation. Authors reported difference -1264 cm³; 95% CI -1679.6 to -655.9.
visceral adipose tissue volume — HED versus CON; 16 weeks randomized allocation. Authors reported difference -1786.4 cm³; 95% CI -2264.6 to -1321.2.
visceral adipose tissue volume — HED versus DCON; 16 weeks randomized allocation. Authors reported difference -1120.4 cm³; 95% CI -1746.6 to -639.4.
Additional authors-reported context: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred. Comparison mapping remains unresolved.
Additional authors-reported context: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review. Comparison mapping remains unresolved.
four arm randomized trial secondary analysis. 82 randomized participants. Population: persons living with type 2 diabetes. Analysis population: unclear. Fields not recorded or incorporated in this summary may still be present in the paper.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
Four-arm fat-loss comparisons
Stable finding ID: finding:examine2025:39427878:1. Finding version: 2. Revision: finding:examine2025:39427878:1:v2. Content hash: sha256:0824e4729c3ba29467ef20f525122a084683c294902222ce7cb49818344cc756.
Paper version: 3. Paper content hash: sha256:a3554d0839e13991d734b5b285aba1f60f9749cfae423f6da442b652db6fb500.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Randomized arm counts: CON 21; HED 21; MED 20; DCON 20.
four arm randomized trial secondary analysis. 82 randomized participants. Population: persons living with type 2 diabetes. Analysis population: unclear. Fields not recorded or incorporated in this summary may still be present in the paper.
Authors-reported finding: Randomized arm counts: CON 21; HED 21; MED 20; DCON 20..
Authors-reported finding: fat mass percentage — DCON versus CON; 16 weeks randomized allocation. Authors reported MD -3.5 fat-mass percentage points; 95% CI -5.6 to -1.4..
Authors-reported finding: fat mass percentage — MED versus CON; 16 weeks randomized allocation. Authors reported MD -6.3 fat-mass percentage points; 95% CI -8.4 to -4.1..
Authors-reported finding: fat mass percentage — HED versus CON; 16 weeks randomized allocation. Authors reported MD -8 fat-mass percentage points; 95% CI -10.2 to -5.8..
Authors-reported finding: fat mass percentage — MED versus DCON; 16 weeks randomized allocation. Authors reported MD -2.8 fat-mass percentage points; 95% CI -4.9 to -0.7..
Authors-reported finding: fat mass percentage — HED versus DCON; 16 weeks randomized allocation. Authors reported MD -4.5 fat-mass percentage points; 95% CI -6.6 to -2.4..
Authors-reported finding: fat mass percentage — HED versus MED; 16 weeks randomized allocation. Authors reported MD -1.8 fat-mass percentage points; 95% CI -3.9 to 0.4..
Authors-reported finding: visceral adipose tissue volume — DCON versus CON; 16 weeks randomized allocation. Authors reported difference -666 cm³; 95% CI -912.8 to -385.1..
Authors-reported finding: visceral adipose tissue volume — MED versus CON; 16 weeks randomized allocation. Authors reported difference -1264 cm³; 95% CI -1679.6 to -655.9..
Authors-reported finding: visceral adipose tissue volume — HED versus CON; 16 weeks randomized allocation. Authors reported difference -1786.4 cm³; 95% CI -2264.6 to -1321.2..
Authors-reported finding: visceral adipose tissue volume — HED versus DCON; 16 weeks randomized allocation. Authors reported difference -1120.4 cm³; 95% CI -1746.6 to -639.4..
Authors-reported finding: Additional authors-reported context: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred. Comparison mapping remains unresolved..
Authors-reported finding: Additional authors-reported context: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review. Comparison mapping remains unresolved..
Each record retains its source-reported context and uncertainty.
Reported limitation: Authors-reported study comparisons and phases; no platform pooling.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Only independently source-stated VAT numeric contrasts are represented.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Only independently source-stated VAT numeric contrasts are represented.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Only independently source-stated VAT numeric contrasts are represented.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Reported limitation: Secondary analysis of a four-arm randomized trial.
Reported limitation: Adjustment and analysis population are not established by this extraction.
Reported limitation: Allocation counts are not analyzed sample sizes.
Reported limitation: Authors-reported contrasts; no platform synthesis or component-level attribution.
Reported limitation: Only independently source-stated VAT numeric contrasts are represented.
Reported limitation: Study population: persons living with type 2 diabetes.
Reported limitation: Authors report no differences in the remaining VAT comparisons; named contrast mapping is not extracted, and no equivalence is inferred.
Reported limitation: Authors report fat-free mass decrease in DCON and MED and preservation in HED, with an HED reported estimate of -0.2% (95% CI -2% to 1.7%). Its exact estimand and comparison are not encoded as a numeric contrast and require review.
Finding revision: finding:examine2025:39427878:1:v2.
Finding version: 2.
Finding content hash: sha256:0824e4729c3ba29467ef20f525122a084683c294902222ce7cb49818344cc756.
Paper version: 3.
Paper version content hash: sha256:a3554d0839e13991d734b5b285aba1f60f9749cfae423f6da442b652db6fb500.
Source content hash: sha256:9ba63140dcc2190fe6c2e1dc2e929ea14f8f5218f758f11d11df9b196302f5ef.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: study_comparisons.clause0 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:2293-2639; study_comparisons.clause1 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:2640-2690; study_comparisons.clause2 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:2790-3004; study_comparisons.clause3 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:3005-3131; study_comparisons.clause4 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:3132-3207; study_comparisons.clause5 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:2691-2780; study_comparisons.clause6 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:3329-3558; study_comparisons.clause7 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:3559-3710; study_comparisons.clause8 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:3208-3328; study_comparisons.clause9 → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text: abstract:2354-2389.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39427878&rettype=abstract&retmode=text. Source hash: sha256:9ba63140dcc2190fe6c2e1dc2e929ea14f8f5218f758f11d11df9b196302f5ef. Locators: study_comparisons.clause0: abstract:2293-2639; study_comparisons.clause1: abstract:2640-2690; study_comparisons.clause2: abstract:2790-3004; study_comparisons.clause3: abstract:3005-3131; study_comparisons.clause4: abstract:3132-3207; study_comparisons.clause5: abstract:2691-2780; study_comparisons.clause6: abstract:3329-3558; study_comparisons.clause7: abstract:3559-3710; study_comparisons.clause8: abstract:3208-3328; study_comparisons.clause9: abstract:2354-2389; study_comparisons.clause0: abstract:2293-2639; study_comparisons.clause1: abstract:2640-2690; study_comparisons.clause2: abstract:2790-3004; study_comparisons.clause3: abstract:3005-3131; study_comparisons.clause4: abstract:3132-3207; study_comparisons.clause5: abstract:2691-2780; study_comparisons.clause6: abstract:3329-3558; study_comparisons.clause7: abstract:3559-3710; study_comparisons.clause8: abstract:3208-3328; study_comparisons.clause9: abstract:2354-2389; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8; sourceTopic.typedRole: Abstract, source context clause 9; sourceTopic.typedRole: Abstract, source context clause 10; study_comparisons.clause0: abstract:2293-2639; study_comparisons.clause1: abstract:2640-2690; study_comparisons.clause2: abstract:2790-3004; study_comparisons.clause3: abstract:3005-3131; study_comparisons.clause4: abstract:3132-3207; study_comparisons.clause5: abstract:2691-2780; study_comparisons.clause6: abstract:3329-3558; study_comparisons.clause7: abstract:3559-3710; study_comparisons.clause8: abstract:3208-3328; study_comparisons.clause9: abstract:2354-2389; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8; sourceTopic.typedRole: Abstract, source context clause 9; sourceTopic.typedRole: Abstract, source context clause 10; study_comparisons.clause0: abstract:2293-2639; study_comparisons.clause1: abstract:2640-2690; study_comparisons.clause2: abstract:2790-3004; study_comparisons.clause3: abstract:3005-3131; study_comparisons.clause4: abstract:3132-3207; study_comparisons.clause5: abstract:2691-2780; study_comparisons.clause6: abstract:3329-3558; study_comparisons.clause7: abstract:3559-3710; study_comparisons.clause8: abstract:3208-3328; study_comparisons.clause9: abstract:2354-2389; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; sourceTopic.typedRole: Abstract, source context clause 4; sourceTopic.typedRole: Abstract, source context clause 5; sourceTopic.typedRole: Abstract, source context clause 6; sourceTopic.typedRole: Abstract, source context clause 7; sourceTopic.typedRole: Abstract, source context clause 8; sourceTopic.typedRole: Abstract, source context clause 9; sourceTopic.typedRole: Abstract, source context clause 10.
Canonical paper: /studies/39427878. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39488067 · finding version 2 · paper version 3
PMID 39488067: Patient Health Questionnaire-9AI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9): favours the studied intervention.
Studied combination: creatine + CBT.
One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression; randomised. creatine+CBT versus placebo+CBT. Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9) at 8 weeks PHQ-9 scores.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported a direction only for Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9): favours the studied intervention.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression; randomised. creatine+CBT versus placebo+CBT. Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9) at 8 weeks PHQ-9 scores.
Source
PMID 39488067 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: favours the studied intervention.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression
Study design
randomised
Analysis population
unclear
Covariate adjustment
Source reports adjustment
Studied intervention
creatine+CBT
Studied combination
creatine + CBT
Comparator
placebo+CBT
Measured outcome
Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9)
Timepoint
8 weeks PHQ-9 scores
Limitations and extraction boundaries
Abstract reports adjusted mean-difference estimate −5.12 but no CI or p-value in that sentence; not encoded as an arm mean or recomputed effect.
Trial is explicitly pilot feasibility/exploratory and hypothesis-generating; authors say longer and larger trials warranted.
Authors report lower PHQ-9 scores in both arms, significantly more so with creatine (adjusted mean difference −5.12); adjustment factors stated: age, sex, and baseline depression score. Abstract sentence supplies no CI or p-value. Numeric result retained as source-reported context; not converted to an arm summary or recomputed.
You can stop here, or inspect the evidence and its original sources.
One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression; randomised. creatine+CBT versus placebo+CBT. Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9) at 8 weeks PHQ-9 scores.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 39488067: Patient Health Questionnaire-9
Stable finding ID: finding:examine2025:39488067:1. Finding version: 2. Revision: finding:examine2025:39488067:1:v2. Content hash: sha256:f022e3f90aa4e019338135c6232baad649c6b0846844aff223bbc08b4cff2a02.
Paper version: 3. Paper content hash: sha256:4205bb6bfa1ea510ec5a9c6ad617f6bc167bb26c6587b3d3ffc800438620cc82.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9): favours the studied intervention.
Studied combination: creatine + CBT.
One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression; randomised. creatine+CBT versus placebo+CBT. Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9) at 8 weeks PHQ-9 scores.
Participants / population: One-hundred participants (50 females, mean age= 30.4 ± 7.4 years) with depression.
Study design: randomised.
Analysis population: unclear.
Covariate adjustment: Source reports adjustment.
Studied intervention: creatine+CBT.
Studied combination: creatine + CBT.
Studied route / context: Not encoded in this record.
Comparator: placebo+CBT.
Measured outcome: Patient Health Questionnaire-9 depression score (Patient Health Questionnaire-9).
Timepoint: 8 weeks PHQ-9 scores.
Source-reported direction: favours the studied intervention. Direction only; no numerical magnitude is available in this record.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Abstract reports adjusted mean-difference estimate −5.12 but no CI or p-value in that sentence; not encoded as an arm mean or recomputed effect.
Reported limitation: Trial is explicitly pilot feasibility/exploratory and hypothesis-generating; authors say longer and larger trials warranted.
Reported limitation: Authors report lower PHQ-9 scores in both arms, significantly more so with creatine (adjusted mean difference −5.12); adjustment factors stated: age, sex, and baseline depression score. Abstract sentence supplies no CI or p-value. Numeric result retained as source-reported context; not converted to an arm summary or recomputed.
Finding revision: finding:examine2025:39488067:1:v2.
Finding version: 2.
Finding content hash: sha256:f022e3f90aa4e019338135c6232baad649c6b0846844aff223bbc08b4cff2a02.
Paper version: 3.
Paper version content hash: sha256:4205bb6bfa1ea510ec5a9c6ad617f6bc167bb26c6587b3d3ffc800438620cc82.
Source content hash: sha256:15ddfa7aea2e7b9e987501ef5325a5fc8629b21c851fc429b1c99d744fd93cbd.
Extraction policy: context164-source-topic-policy:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction policy hash: sha256:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, participants; applicability.adjustment → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, statistical analysis, adjustment context; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, randomized arms; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, intervention components; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, randomized arms; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, randomized assignment; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, primary efficacy outcome; applicability.instrument → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, instrument; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, participant count; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, authors reported result; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text: Abstract, authors reported result.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39488067&rettype=abstract&retmode=text. Source hash: sha256:15ddfa7aea2e7b9e987501ef5325a5fc8629b21c851fc429b1c99d744fd93cbd. Locators: applicability.population: Abstract, participants; applicability.adjustment: Abstract, statistical analysis, adjustment context; applicability.experimentalIntervention: Abstract, randomized arms; applicability.experimentalInterventionComponents: Abstract, intervention components; applicability.comparator: Abstract, randomized arms; applicability.design: Abstract, randomized assignment; applicability.outcomeConstruct: Abstract, primary efficacy outcome; applicability.instrument: Abstract, instrument; applicability.participantMetric: Abstract, participant count; reportedDirection: Abstract, authors reported result; limitations: Abstract, authors reported result; applicability.population: Abstract, participants; applicability.adjustment: Abstract, statistical analysis, adjustment context; applicability.experimentalIntervention: Abstract, randomized arms; applicability.experimentalInterventionComponents: Abstract, intervention components; applicability.comparator: Abstract, randomized arms; applicability.design: Abstract, randomized assignment; applicability.outcomeConstruct: Abstract, primary efficacy outcome; applicability.instrument: Abstract, instrument; applicability.participantMetric: Abstract, participant count; reportedDirection: Abstract, authors reported result; limitations: Abstract, authors reported result; applicability.population: Abstract, participants; applicability.adjustment: Abstract, statistical analysis, adjustment context; applicability.experimentalIntervention: Abstract, randomized arms; applicability.experimentalInterventionComponents: Abstract, intervention components; applicability.comparator: Abstract, randomized arms; applicability.design: Abstract, randomized assignment; applicability.outcomeConstruct: Abstract, primary efficacy outcome; applicability.instrument: Abstract, instrument; applicability.participantMetric: Abstract, participant count; reportedDirection: Abstract, authors reported result; limitations: Abstract, authors reported result; applicability.timepoint: Abstract, week-8 endpoint.
Canonical paper: /studies/39488067. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39498904 · finding version 2 · paper version 3
PMID 39498904: Computerized Mental Performance Assessment System (COMPASS)AI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)): favours the studied intervention.
Reported p < 0.05.
Studied route/context: orally.
adults with self-reported cognitive and energy problems; prospective, randomized, placebo-controlled study. Ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day versus identical placebo. episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)) at 8 week baseline.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported a direction only for episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)): favours the studied intervention.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
adults with self-reported cognitive and energy problems; prospective, randomized, placebo-controlled study. Ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day versus identical placebo. episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)) at 8 week baseline.
Source
PMID 39498904 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: favours the studied intervention.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
adults with self-reported cognitive and energy problems
episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS))
Timepoint
8 week baseline
Limitations and extraction boundaries
One generalized p<.05 statement covers the listed three COMPASS items; no item-specific significance, effect sizes, confidence intervals, or exact p-values are given.
Other outcomes with baseline changes and reported safety are retained in inventory; the abstract does not clearly state between-group inferential comparisons for those outcomes.
The abstract describes participants as healthy subjects aged 30–75 years and separately as adults with self-reported cognitive and energy problems; the population field anchors the latter, and both descriptions are retained.
Authors report greater improvement from baseline with ARE versus placebo across the three COMPASS items, with one generalized p<0.05 statement for the bundle; do not assign significance separately to each item.
You can stop here, or inspect the evidence and its original sources.
adults with self-reported cognitive and energy problems; prospective, randomized, placebo-controlled study. Ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day versus identical placebo. episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)) at 8 week baseline.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 39498904: Computerized Mental Performance Assessment System (COMPASS)
Stable finding ID: finding:examine2025:39498904:1. Finding version: 2. Revision: finding:examine2025:39498904:1:v2. Content hash: sha256:6a0e3fef7184bca77a0b877d1413ab53339e1cc8b14fa3444a90edd657f9def5.
Paper version: 3. Paper content hash: sha256:ec8bb69480bfe47eebdd69054aed9ba008f5f0094b77c290b5e44e542554b410.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Authors reported a direction only for episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)): favours the studied intervention.
Studied route/context: orally.
adults with self-reported cognitive and energy problems; prospective, randomized, placebo-controlled study. Ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day versus identical placebo. episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)) at 8 week baseline.
Participants / population: adults with self-reported cognitive and energy problems.
Study design: prospective, randomized, placebo-controlled study.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: Ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day.
Studied combination: Not encoded in this record.
Studied route / context: orally.
Comparator: identical placebo.
Measured outcome: episodic memory, working memory, and accuracy of attention (Computerized Mental Performance Assessment System (COMPASS)).
Timepoint: 8 week baseline.
Source-reported direction: favours the studied intervention. Direction only; no numerical magnitude is available in this record.
Reported p < 0.05.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: One generalized p<.05 statement covers the listed three COMPASS items; no item-specific significance, effect sizes, confidence intervals, or exact p-values are given.
Reported limitation: Other outcomes with baseline changes and reported safety are retained in inventory; the abstract does not clearly state between-group inferential comparisons for those outcomes.
Reported limitation: The abstract describes participants as healthy subjects aged 30–75 years and separately as adults with self-reported cognitive and energy problems; the population field anchors the latter, and both descriptions are retained.
Reported limitation: Authors report greater improvement from baseline with ARE versus placebo across the three COMPASS items, with one generalized p<0.05 statement for the bundle; do not assign significance separately to each item.
Finding revision: finding:examine2025:39498904:1:v2.
Finding version: 2.
Finding content hash: sha256:6a0e3fef7184bca77a0b877d1413ab53339e1cc8b14fa3444a90edd657f9def5.
Paper version: 3.
Paper version content hash: sha256:ec8bb69480bfe47eebdd69054aed9ba008f5f0094b77c290b5e44e542554b410.
Source content hash: sha256:4a7d7a515cd2be4b73df686d82b0b12d4eef89b1a89e67a5bfad5724779bc69b.
Extraction policy: context164-source-topic-policy:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction policy hash: sha256:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; applicability.experimentalInterventionRoute → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: Abstract, route/duration; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: Abstract, design; applicability.instrument → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: Abstract, instrument; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; reportedSignificance.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text: Abstract, bundled significance result.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39498904&rettype=abstract&retmode=text. Source hash: sha256:4a7d7a515cd2be4b73df686d82b0b12d4eef89b1a89e67a5bfad5724779bc69b. Locators: applicability.population: PubMed abstract, exact acquired sentence context; applicability.experimentalIntervention: PubMed abstract, exact acquired sentence context; applicability.experimentalInterventionRoute: Abstract, route/duration; applicability.comparator: PubMed abstract, exact acquired sentence context; applicability.design: Abstract, design; applicability.instrument: Abstract, instrument; applicability.outcomeConstruct: PubMed abstract, exact acquired sentence context; applicability.participantMetric: PubMed abstract, exact acquired sentence context; reportedDirection: PubMed abstract, exact acquired sentence context; limitations: PubMed abstract, exact acquired sentence context; reportedSignificance.value: Abstract, bundled significance result; applicability.population: PubMed abstract, exact acquired sentence context; applicability.experimentalIntervention: PubMed abstract, exact acquired sentence context; applicability.experimentalInterventionRoute: Abstract, route/duration; applicability.comparator: PubMed abstract, exact acquired sentence context; applicability.design: Abstract, design; applicability.instrument: Abstract, instrument; applicability.outcomeConstruct: PubMed abstract, exact acquired sentence context; applicability.participantMetric: PubMed abstract, exact acquired sentence context; reportedDirection: PubMed abstract, exact acquired sentence context; limitations: PubMed abstract, exact acquired sentence context; reportedSignificance.value: Abstract, bundled significance result; applicability.population: PubMed abstract, exact acquired sentence context; applicability.experimentalIntervention: PubMed abstract, exact acquired sentence context; applicability.experimentalInterventionRoute: Abstract, route/duration; applicability.comparator: PubMed abstract, exact acquired sentence context; applicability.design: Abstract, design; applicability.instrument: Abstract, instrument; applicability.outcomeConstruct: PubMed abstract, exact acquired sentence context; applicability.participantMetric: PubMed abstract, exact acquired sentence context; reportedDirection: PubMed abstract, exact acquired sentence context; limitations: PubMed abstract, exact acquired sentence context; reportedSignificance.value: Abstract, bundled significance result; applicability.timepoint: Abstract, baseline/week-8 assessment.
Canonical paper: /studies/39498904. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39751920 · finding version 2 · paper version 3
PMID 39751920: skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB)AI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) remains unresolved in this record.
Reported p < 0.05.
Studied combination: protein.
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) at 12 week study.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Direction for skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) remains unresolved in this record.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) at 12 week study.
Source
PMID 39751920 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: unclear.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old)
Study design
12-week randomized, controlled, parallel pilot study
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
1.2-1.5 g/kg/day of protein
Studied combination
protein
Comparator
0.8-1.0 g/kg/day
Measured outcome
skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB)
Timepoint
12 week study
Limitations and extraction boundaries
Pilot study with 26 participants and 12-week duration; abstract does not give allocation Ns or arm means/SDs.
The abstract reports statistical outcomes but not enough arm-level data for numerical descriptive summaries.
The authors report that progression of T2DM was not interrupted.
Authors report different between-group kinetics for the five named muscle/performance outcomes (p<0.05) but the abstract does not give a coherent direction for this bundle; do not infer direction from separate within-arm changes.
You can stop here, or inspect the evidence and its original sources.
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) at 12 week study.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 39751920: skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB)
Stable finding ID: finding:examine2025:39751920:1. Finding version: 2. Revision: finding:examine2025:39751920:1:v2. Content hash: sha256:3157dbf12fbb494fe95b181fc744575591b9311e84430280b0ff9963107b3173.
Paper version: 3. Paper content hash: sha256:97ce820e6897cc437043e94354306ae5180b9492916e7a003df0169f942f9e60.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) remains unresolved in this record.
Studied combination: protein.
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB) at 12 week study.
Participants / population: 26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old).
Study design: 12-week randomized, controlled, parallel pilot study.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: 1.2-1.5 g/kg/day of protein.
Studied combination: protein.
Studied route / context: Not encoded in this record.
Comparator: 0.8-1.0 g/kg/day.
Measured outcome: skeletal muscle index (SMI), appendicular lean mass (ALM), hand grip strength (HGS), gait speed (GS), standing balance (SB).
Timepoint: 12 week study.
Source-reported direction: unclear. Direction only; no numerical magnitude is available in this record.
Reported p < 0.05.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Pilot study with 26 participants and 12-week duration; abstract does not give allocation Ns or arm means/SDs.
Reported limitation: The abstract reports statistical outcomes but not enough arm-level data for numerical descriptive summaries.
Reported limitation: The authors report that progression of T2DM was not interrupted.
Reported limitation: Authors report different between-group kinetics for the five named muscle/performance outcomes (p<0.05) but the abstract does not give a coherent direction for this bundle; do not infer direction from separate within-arm changes.
Finding revision: finding:examine2025:39751920:1:v2.
Finding version: 2.
Finding content hash: sha256:3157dbf12fbb494fe95b181fc744575591b9311e84430280b0ff9963107b3173.
Paper version: 3.
Paper version content hash: sha256:97ce820e6897cc437043e94354306ae5180b9492916e7a003df0169f942f9e60.
Source content hash: sha256:b9cef0516a18ba74e108d04d623157a3d3f27962bf55a6d290058c9d6be69779.
Extraction policy: context164-source-topic-policy:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction policy hash: sha256:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, participant context; applicability.timepoint → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, reported study timing; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, author-reported results; reportedSignificance.value → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, p-value; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, author-reported results.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text. Source hash: sha256:b9cef0516a18ba74e108d04d623157a3d3f27962bf55a6d290058c9d6be69779. Locators: applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; reportedSignificance.value: PubMed abstract, p-value; limitations: PubMed abstract, author-reported results; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; reportedSignificance.value: PubMed abstract, p-value; limitations: PubMed abstract, author-reported results; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; reportedSignificance.value: PubMed abstract, p-value; limitations: PubMed abstract, author-reported results; applicability.timepoint: PubMed abstract, reported study timing.
Canonical paper: /studies/39751920. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39751920 · finding version 2 · paper version 3
PMID 39751920: metabolic markers indicesAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for metabolic markers indices remains unresolved in this record.
Studied combination: protein.
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. metabolic markers indices at 12 week study.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Direction for metabolic markers indices remains unresolved in this record.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. metabolic markers indices at 12 week study.
Source
PMID 39751920 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: unclear.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old)
Study design
12-week randomized, controlled, parallel pilot study
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
1.2-1.5 g/kg/day of protein
Studied combination
protein
Comparator
0.8-1.0 g/kg/day
Measured outcome
metabolic markers indices
Timepoint
12 week study
Limitations and extraction boundaries
Pilot study with 26 participants and 12-week duration; abstract does not give allocation Ns or arm means/SDs.
The abstract reports statistical outcomes but not enough arm-level data for numerical descriptive summaries.
The authors report that progression of T2DM was not interrupted.
Authors describe metabolic-marker kinetics as similar between groups. This is a separate source-reported similarity/null finding; no exact p-value or numerical contrast is provided.
The source describes metabolic-marker kinetics as similar for both groups; the qualitative DTO does not encode similarity as a statistical no-difference result.
You can stop here, or inspect the evidence and its original sources.
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. metabolic markers indices at 12 week study.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 39751920: metabolic markers indices
Stable finding ID: finding:examine2025:39751920:2. Finding version: 2. Revision: finding:examine2025:39751920:2:v2. Content hash: sha256:29f109ccd162cc76cd3e00c2546755871e0823fbf4d12509fefd95a66fb06570.
Paper version: 3. Paper content hash: sha256:97ce820e6897cc437043e94354306ae5180b9492916e7a003df0169f942f9e60.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for metabolic markers indices remains unresolved in this record.
Studied combination: protein.
26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old); 12-week randomized, controlled, parallel pilot study. 1.2-1.5 g/kg/day of protein versus 0.8-1.0 g/kg/day. metabolic markers indices at 12 week study.
Participants / population: 26 patients diagnosed with T2DM and had either low muscle mass, or low muscle strength or poor physical performance (age > 55 years old).
Study design: 12-week randomized, controlled, parallel pilot study.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: 1.2-1.5 g/kg/day of protein.
Studied combination: protein.
Studied route / context: Not encoded in this record.
Comparator: 0.8-1.0 g/kg/day.
Measured outcome: metabolic markers indices.
Timepoint: 12 week study.
Source-reported direction: unclear. Direction only; no numerical magnitude is available in this record.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Pilot study with 26 participants and 12-week duration; abstract does not give allocation Ns or arm means/SDs.
Reported limitation: The abstract reports statistical outcomes but not enough arm-level data for numerical descriptive summaries.
Reported limitation: The authors report that progression of T2DM was not interrupted.
Reported limitation: Authors describe metabolic-marker kinetics as similar between groups. This is a separate source-reported similarity/null finding; no exact p-value or numerical contrast is provided.
Reported limitation: The source describes metabolic-marker kinetics as similar for both groups; the qualitative DTO does not encode similarity as a statistical no-difference result.
Finding revision: finding:examine2025:39751920:2:v2.
Finding version: 2.
Finding content hash: sha256:29f109ccd162cc76cd3e00c2546755871e0823fbf4d12509fefd95a66fb06570.
Paper version: 3.
Paper version content hash: sha256:97ce820e6897cc437043e94354306ae5180b9492916e7a003df0169f942f9e60.
Source content hash: sha256:b9cef0516a18ba74e108d04d623157a3d3f27962bf55a6d290058c9d6be69779.
Extraction policy: context164-source-topic-policy:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction policy hash: sha256:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, participant context; applicability.timepoint → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, reported study timing; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, author-reported results; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text: PubMed abstract, author-reported results.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39751920&rettype=abstract&retmode=text. Source hash: sha256:b9cef0516a18ba74e108d04d623157a3d3f27962bf55a6d290058c9d6be69779. Locators: applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; limitations: PubMed abstract, author-reported results; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; limitations: PubMed abstract, author-reported results; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; limitations: PubMed abstract, author-reported results; applicability.timepoint: PubMed abstract, reported study timing.
Canonical paper: /studies/39751920. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39776171 · finding version 2 · paper version 3
all-causeAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
Source statement 1
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
Source statement 2
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Source statement 3
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Source
PMID 39776171 · finding version 2
Each record retains its source-reported context and uncertainty.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Exact source-reported statements
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Authors-reported finding
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
Authors-reported finding
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Authors-reported finding
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
Limitations and extraction boundaries
Observational association only; not a causal effect.
Adjusted HR compares with non-coffee drinking; the paper also identified an all-day pattern.
Adjustment includes other confounders, which the abstract does not enumerate.
The outcome field names the abstract wording before its reported ratio; the paired measure and interval remain separately source-anchored in statistic.
You can stop here, or inspect the evidence and its original sources.
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
all-cause
Stable finding ID: finding:examine2025:39776171:1. Finding version: 2. Revision: finding:examine2025:39776171:1:v2. Content hash: sha256:d4931652a794b42ee47f4ce38deeed20e64f5a8e5a520d91f08a0cc332755292.
Paper version: 3. Paper content hash: sha256:a0ba32673321b70b9a18d29dd29814aa7e916c938c4c940494ec02a15af810e4.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95.
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Authors-reported finding: Authors reported Hazard ratio 0.84; 95% CI 0.74 to 0.95..
Authors-reported finding: Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders..
Authors-reported finding: Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years..
Each record retains its source-reported context and uncertainty.
Reported limitation: Observational association only; not a causal effect.
Reported limitation: Adjusted HR compares with non-coffee drinking; the paper also identified an all-day pattern.
Reported limitation: Adjustment includes other confounders, which the abstract does not enumerate.
Reported limitation: The outcome field names the abstract wording before its reported ratio; the paired measure and interval remain separately source-anchored in statistic.
Finding revision: finding:examine2025:39776171:1:v2.
Finding version: 2.
Finding content hash: sha256:d4931652a794b42ee47f4ce38deeed20e64f5a8e5a520d91f08a0cc332755292.
Paper version: 3.
Paper version content hash: sha256:a0ba32673321b70b9a18d29dd29814aa7e916c938c4c940494ec02a15af810e4.
Source content hash: sha256:c1db8468872ec53da1c1bd2f24061d9dd26dbf8aad6f686c71278bd7a3be6161.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; exposure → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; comparison → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; outcome → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; sourceContext → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; statistic → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; adjustment → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; timeframe → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text. Source hash: sha256:c1db8468872ec53da1c1bd2f24061d9dd26dbf8aad6f686c71278bd7a3be6161. Locators: design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; timeframe: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; timeframe: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; timeframe: PubMed abstract, author-reported association.
Canonical paper: /studies/39776171. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39776171 · finding version 2 · paper version 3
cardiovascular disease-specificAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
Source statement 1
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
Source statement 2
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Source statement 3
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Source
PMID 39776171 · finding version 2
Each record retains its source-reported context and uncertainty.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Exact source-reported statements
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Authors-reported finding
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
Authors-reported finding
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Authors-reported finding
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
Limitations and extraction boundaries
Observational association only; not a causal effect.
Adjusted HR compares with non-coffee drinking; the paper also identified an all-day pattern.
Adjustment includes other confounders, which the abstract does not enumerate.
The outcome field names the abstract wording before its reported ratio; the paired measure and interval remain separately source-anchored in statistic.
You can stop here, or inspect the evidence and its original sources.
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders.
Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years.
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
cardiovascular disease-specific
Stable finding ID: finding:examine2025:39776171:2. Finding version: 2. Revision: finding:examine2025:39776171:2:v2. Content hash: sha256:021089d3c150a1632397dfa9c5eb9502cf518d21366c249f0339ce76a75fd5c7.
Paper version: 3. Paper content hash: sha256:a0ba32673321b70b9a18d29dd29814aa7e916c938c4c940494ec02a15af810e4.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87.
In this observational study. Population: 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018. morning-type pattern compared with as compared with non-coffee drinking. Association only; causality is not established.
Authors-reported finding: Authors reported Hazard ratio 0.69; 95% CI 0.55 to 0.87..
Authors-reported finding: Adjustment: After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders..
Authors-reported finding: Timeframe: median (interquartile range) follow-up of 9.8 (9.1) years..
Each record retains its source-reported context and uncertainty.
Reported limitation: Observational association only; not a causal effect.
Reported limitation: Adjusted HR compares with non-coffee drinking; the paper also identified an all-day pattern.
Reported limitation: Adjustment includes other confounders, which the abstract does not enumerate.
Reported limitation: The outcome field names the abstract wording before its reported ratio; the paired measure and interval remain separately source-anchored in statistic.
Finding revision: finding:examine2025:39776171:2:v2.
Finding version: 2.
Finding content hash: sha256:021089d3c150a1632397dfa9c5eb9502cf518d21366c249f0339ce76a75fd5c7.
Paper version: 3.
Paper version content hash: sha256:a0ba32673321b70b9a18d29dd29814aa7e916c938c4c940494ec02a15af810e4.
Source content hash: sha256:c1db8468872ec53da1c1bd2f24061d9dd26dbf8aad6f686c71278bd7a3be6161.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; exposure → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; comparison → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; outcome → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; sourceContext → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; statistic → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; adjustment → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association; timeframe → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text: PubMed abstract, author-reported association.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39776171&rettype=abstract&retmode=text. Source hash: sha256:c1db8468872ec53da1c1bd2f24061d9dd26dbf8aad6f686c71278bd7a3be6161. Locators: design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; timeframe: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; timeframe: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; timeframe: PubMed abstract, author-reported association.
Canonical paper: /studies/39776171. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39867555 · finding version 2 · paper version 3
cancer riskAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: 25,879 participants aged 20 years and older. dietary creatine intake compared with For each standard deviation (SD) increase in dietary creatine intake. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
Source statement 1
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
Source statement 2
Adjustment: adjusted odds ratio.
Source statement 3
Timeframe: not recorded in this summary.
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: 25,879 participants aged 20 years and older. dietary creatine intake compared with For each standard deviation (SD) increase in dietary creatine intake. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Source
PMID 39867555 · finding version 2
Each record retains its source-reported context and uncertainty.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Exact source-reported statements
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: 25,879 participants aged 20 years and older. dietary creatine intake compared with For each standard deviation (SD) increase in dietary creatine intake. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
Adjustment: adjusted odds ratio.
Timeframe: not recorded in this summary.
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Authors-reported finding
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
Authors-reported finding
Adjustment: adjusted odds ratio.
Authors-reported finding
Timeframe: not recorded in this summary.
Limitations and extraction boundaries
Observational association only; not causal.
Abstract does not specify model adjustment covariates or follow-up time.
You can stop here, or inspect the evidence and its original sources.
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
Adjustment: adjusted odds ratio.
Timeframe: not recorded in this summary.
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: 25,879 participants aged 20 years and older. dietary creatine intake compared with For each standard deviation (SD) increase in dietary creatine intake. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
cancer risk
Stable finding ID: finding:examine2025:39867555:1. Finding version: 2. Revision: finding:examine2025:39867555:1:v2. Content hash: sha256:7a6cafc1bdd82f649cb92250dbfc8375f9458e07e40ac44f67ff31567c23c7e2.
Paper version: 3. Paper content hash: sha256:410d6f26ec7a9e9b219d9c055f802c67939ad0ac83b8fddb03bd6821485ed711.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025.
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: 25,879 participants aged 20 years and older. dietary creatine intake compared with For each standard deviation (SD) increase in dietary creatine intake. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Authors-reported finding: Authors reported Odds ratio 0.95; 95% CI 0.91 to 0.99; p = 0.025..
Authors-reported finding: Adjustment: adjusted odds ratio..
Authors-reported finding: Timeframe: not recorded in this summary..
Each record retains its source-reported context and uncertainty.
Reported limitation: Observational association only; not causal.
Reported limitation: Abstract does not specify model adjustment covariates or follow-up time.
Finding revision: finding:examine2025:39867555:1:v2.
Finding version: 2.
Finding content hash: sha256:7a6cafc1bdd82f649cb92250dbfc8375f9458e07e40ac44f67ff31567c23c7e2.
Paper version: 3.
Paper version content hash: sha256:410d6f26ec7a9e9b219d9c055f802c67939ad0ac83b8fddb03bd6821485ed711.
Source content hash: sha256:c62911b2f7aa4f073c236028850a2a19acb3014f795aa13d6eeb5f1e13e8a23b.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; exposure → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; comparison → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; outcome → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; sourceContext → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; statistic → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; adjustment → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; pValue → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text. Source hash: sha256:c62911b2f7aa4f073c236028850a2a19acb3014f795aa13d6eeb5f1e13e8a23b. Locators: design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; pValue: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; pValue: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; pValue: PubMed abstract, author-reported association.
Canonical paper: /studies/39867555. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 39867555 · finding version 2 · paper version 3
cancer riskAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: participants aged 20 years and older. age compared with For each SD increase in age. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
Source statement 1
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
Source statement 2
Adjustment: adjusted OR.
Source statement 3
Timeframe: not recorded in this summary.
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
Who & when
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: participants aged 20 years and older. age compared with For each SD increase in age. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Source
PMID 39867555 · finding version 2
Each record retains its source-reported context and uncertainty.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Exact source-reported statements
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: participants aged 20 years and older. age compared with For each SD increase in age. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
Adjustment: adjusted OR.
Timeframe: not recorded in this summary.
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Authors-reported finding
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
Authors-reported finding
Adjustment: adjusted OR.
Authors-reported finding
Timeframe: not recorded in this summary.
Limitations and extraction boundaries
This is the authors’ age-risk association, not a creatine exposure effect.
Observational association only; not causal.
Abstract does not specify model adjustment covariates or follow-up time.
You can stop here, or inspect the evidence and its original sources.
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
Adjustment: adjusted OR.
Timeframe: not recorded in this summary.
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: participants aged 20 years and older. age compared with For each SD increase in age. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
cancer risk
Stable finding ID: finding:examine2025:39867555:2. Finding version: 2. Revision: finding:examine2025:39867555:2:v2. Content hash: sha256:c37c07530c87ac0572f28cb3e279e2f8bd9fd4791babe0cbb481dffe98c6d447.
Paper version: 3. Paper content hash: sha256:410d6f26ec7a9e9b219d9c055f802c67939ad0ac83b8fddb03bd6821485ed711.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001.
This study used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. Population: participants aged 20 years and older. age compared with For each SD increase in age. Association only; causality is not established. Fields not recorded or incorporated in this summary may still be present in the paper.
Authors-reported finding: Authors reported Odds ratio 3.27; 95% CI 3.07 to 3.48; p < 0.001..
Authors-reported finding: Adjustment: adjusted OR..
Authors-reported finding: Timeframe: not recorded in this summary..
Each record retains its source-reported context and uncertainty.
Reported limitation: This is the authors’ age-risk association, not a creatine exposure effect.
Reported limitation: Observational association only; not causal.
Reported limitation: Abstract does not specify model adjustment covariates or follow-up time.
Finding revision: finding:examine2025:39867555:2:v2.
Finding version: 2.
Finding content hash: sha256:c37c07530c87ac0572f28cb3e279e2f8bd9fd4791babe0cbb481dffe98c6d447.
Paper version: 3.
Paper version content hash: sha256:410d6f26ec7a9e9b219d9c055f802c67939ad0ac83b8fddb03bd6821485ed711.
Source content hash: sha256:c62911b2f7aa4f073c236028850a2a19acb3014f795aa13d6eeb5f1e13e8a23b.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; exposure → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; comparison → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; outcome → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; sourceContext → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; statistic → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; adjustment → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association; pValue → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text: PubMed abstract, author-reported association.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=39867555&rettype=abstract&retmode=text. Source hash: sha256:c62911b2f7aa4f073c236028850a2a19acb3014f795aa13d6eeb5f1e13e8a23b. Locators: design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; pValue: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; pValue: PubMed abstract, author-reported association; design: PubMed abstract, author-reported association; population: PubMed abstract, author-reported association; exposure: PubMed abstract, author-reported association; comparison: PubMed abstract, author-reported association; outcome: PubMed abstract, author-reported association; sourceContext: PubMed abstract, author-reported association; statistic: PubMed abstract, author-reported association; adjustment: PubMed abstract, author-reported association; pValue: PubMed abstract, author-reported association.
Canonical paper: /studies/39867555. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 40082711 · finding version 2 · paper version 3
PMID 40082711: energy expenditure and energy intakeAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). energy expenditure and energy intake at 54 hours UPF diets.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Direction for energy expenditure and energy intake remains unresolved in this record.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). energy expenditure and energy intake at 54 hours UPF diets.
Source
PMID 40082711 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: unclear.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
21 healthy young adults
Study design
single-blind crossover trial
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF)
Studied combination
high-protein (30%) + lower-carbohydrate (29%)
Comparator
a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF)
Measured outcome
energy expenditure and energy intake
Timepoint
54 hours UPF diets
Limitations and extraction boundaries
Exposure lasted 54 hours in a whole-room calorimeter; meals were consumed ad libitum.
Reported descriptive results are not reinterpreted as prevention of overeating.
Both protein and carbohydrate proportions changed simultaneously; these results are not an isolated protein effect. Numeric contrasts are not encoded as arm values, and the meaning of the reported ± values is not specified in this abstract.
Authors report HPLC-UPF versus NPNC-UPF: higher energy expenditure (128 ± 98 kcal d-1), lower energy intake (−196 ± 396 kcal d-1), and less-positive energy balance (18% versus 32%), with gains in protein and carbohydrate balance only. The abstract does not identify what ± represents. Authors state the short-term diet did not prevent overeating. Protein and carbohydrate proportions changed together; do not infer an isolated protein effect or reinterpret the values.
You can stop here, or inspect the evidence and its original sources.
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). energy expenditure and energy intake at 54 hours UPF diets.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 40082711: energy expenditure and energy intake
Stable finding ID: finding:examine2025:40082711:1. Finding version: 2. Revision: finding:examine2025:40082711:1:v2. Content hash: sha256:f2c4555180f779f6e67c26923bcce245899056576504e7ac26c2d03a4008f1c8.
Paper version: 3. Paper content hash: sha256:6be3d5dca57fb8d9b1c19b7a6da49a18c9f1622aeb4f4052feb946e3a29dd195.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for energy expenditure and energy intake remains unresolved in this record.
Studied combination: high-protein (30%) + lower-carbohydrate (29%).
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). energy expenditure and energy intake at 54 hours UPF diets.
Participants / population: 21 healthy young adults.
Study design: single-blind crossover trial.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF).
Studied combination: high-protein (30%) + lower-carbohydrate (29%).
Studied route / context: Not encoded in this record.
Comparator: a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF).
Measured outcome: energy expenditure and energy intake.
Timepoint: 54 hours UPF diets.
Source-reported direction: unclear. Direction only; no numerical magnitude is available in this record.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Exposure lasted 54 hours in a whole-room calorimeter; meals were consumed ad libitum.
Reported limitation: Reported descriptive results are not reinterpreted as prevention of overeating.
Reported limitation: Both protein and carbohydrate proportions changed simultaneously; these results are not an isolated protein effect. Numeric contrasts are not encoded as arm values, and the meaning of the reported ± values is not specified in this abstract.
Reported limitation: Authors report HPLC-UPF versus NPNC-UPF: higher energy expenditure (128 ± 98 kcal d-1), lower energy intake (−196 ± 396 kcal d-1), and less-positive energy balance (18% versus 32%), with gains in protein and carbohydrate balance only. The abstract does not identify what ± represents. Authors state the short-term diet did not prevent overeating. Protein and carbohydrate proportions changed together; do not infer an isolated protein effect or reinterpret the values.
Finding revision: finding:examine2025:40082711:1:v2.
Finding version: 2.
Finding content hash: sha256:f2c4555180f779f6e67c26923bcce245899056576504e7ac26c2d03a4008f1c8.
Paper version: 3.
Paper version content hash: sha256:6be3d5dca57fb8d9b1c19b7a6da49a18c9f1622aeb4f4052feb946e3a29dd195.
Source content hash: sha256:f81a6b9f221c0f3b305ed5508a82a621c2c069ed93390fd4529727deae570e13.
Extraction policy: context164-source-topic-policy:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction policy hash: sha256:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, participant context; applicability.timepoint → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, reported study timing; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, exact acquired sentence context.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text. Source hash: sha256:f81a6b9f221c0f3b305ed5508a82a621c2c069ed93390fd4529727deae570e13. Locators: applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract, exact acquired sentence context; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, exact acquired sentence context; limitations: PubMed abstract, exact acquired sentence context; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract, exact acquired sentence context; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, exact acquired sentence context; limitations: PubMed abstract, exact acquired sentence context; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract, exact acquired sentence context; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, exact acquired sentence context; limitations: PubMed abstract, exact acquired sentence context; applicability.timepoint: PubMed abstract, reported study timing.
Canonical paper: /studies/40082711. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 40082711 · finding version 2 · paper version 3
PMID 40082711: postprandial ghrelin, glucagon, peptide YYAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). postprandial ghrelin, glucagon, peptide YY at 54 hours UPF diets.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
Direction for postprandial ghrelin, glucagon, peptide YY remains unresolved in this record.
Direction only. No numerical magnitude or uncertainty range is recorded for this finding.
Who & when
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). postprandial ghrelin, glucagon, peptide YY at 54 hours UPF diets.
Source
PMID 40082711 · finding version 2
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Same finding version 2; paper version 3. Exact identity, status and limitations remain in this article.
Source-reported direction
Source-reported direction: unclear.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Studied context
The context this result was produced in. It bounds what the result can be applied to.
Participants / population
21 healthy young adults
Study design
single-blind crossover trial
Analysis population
unclear
Covariate adjustment
Adjustment unresolved in this record
Studied intervention
a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF)
Studied combination
high-protein (30%) + lower-carbohydrate (29%)
Comparator
a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF)
Measured outcome
postprandial ghrelin, glucagon, peptide YY
Timepoint
54 hours UPF diets
Limitations and extraction boundaries
Secondary outcomes; abstract gives no uncertainty or inferential statistics.
Both protein and carbohydrate proportions changed simultaneously; not an isolated protein effect.
Exposure lasted 54 hours in a whole-room calorimeter. The authors report that short-term consumption did not prevent overeating.
Authors report lower postprandial ghrelin and higher glucagon and peptide YY with HPLC-UPF versus NPNC-UPF. These are secondary outcomes; the abstract gives no inferential statistics or uncertainty. The two macronutrient proportions changed together.
You can stop here, or inspect the evidence and its original sources.
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). postprandial ghrelin, glucagon, peptide YY at 54 hours UPF diets.
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
PMID 40082711: postprandial ghrelin, glucagon, peptide YY
Stable finding ID: finding:examine2025:40082711:2. Finding version: 2. Revision: finding:examine2025:40082711:2:v2. Content hash: sha256:68b7f1f021d08f2b22779df0c06cc078edcf83272941f950214b9c77adb62963.
Paper version: 3. Paper content hash: sha256:6be3d5dca57fb8d9b1c19b7a6da49a18c9f1622aeb4f4052feb946e3a29dd195.
AI-extracted — pending human review
Extraction status: machine extracted. Source status is not human clinical review.
Publication status: published. Record review status: not reviewed.
Not poolable: one source-reported result, not a pooled treatment estimate.
Direction for postprandial ghrelin, glucagon, peptide YY remains unresolved in this record.
Studied combination: high-protein (30%) + lower-carbohydrate (29%).
21 healthy young adults; single-blind crossover trial. a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF) versus a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF). postprandial ghrelin, glucagon, peptide YY at 54 hours UPF diets.
Participants / population: 21 healthy young adults.
Study design: single-blind crossover trial.
Analysis population: unclear.
Covariate adjustment: Adjustment unresolved in this record.
Studied intervention: a high-protein (30%) and lower-carbohydrate (29%) diet (HPLC-UPF).
Studied combination: high-protein (30%) + lower-carbohydrate (29%).
Studied route / context: Not encoded in this record.
Comparator: a normal-protein (13%) and normal-carbohydrate (46%) diet (NPNC-UPF).
Measured outcome: postprandial ghrelin, glucagon, peptide YY.
Timepoint: 54 hours UPF diets.
Source-reported direction: unclear. Direction only; no numerical magnitude is available in this record.
No between-arm contrast, interval estimate or pooled result is calculated here; the values above are exactly as the source reported them.
Reported limitation: Secondary outcomes; abstract gives no uncertainty or inferential statistics.
Reported limitation: Both protein and carbohydrate proportions changed simultaneously; not an isolated protein effect.
Reported limitation: Exposure lasted 54 hours in a whole-room calorimeter. The authors report that short-term consumption did not prevent overeating.
Reported limitation: Authors report lower postprandial ghrelin and higher glucagon and peptide YY with HPLC-UPF versus NPNC-UPF. These are secondary outcomes; the abstract gives no inferential statistics or uncertainty. The two macronutrient proportions changed together.
Finding revision: finding:examine2025:40082711:2:v2.
Finding version: 2.
Finding content hash: sha256:68b7f1f021d08f2b22779df0c06cc078edcf83272941f950214b9c77adb62963.
Paper version: 3.
Paper version content hash: sha256:6be3d5dca57fb8d9b1c19b7a6da49a18c9f1622aeb4f4052feb946e3a29dd195.
Source content hash: sha256:f81a6b9f221c0f3b305ed5508a82a621c2c069ed93390fd4529727deae570e13.
Extraction policy: context164-source-topic-policy:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction policy hash: sha256:a2ed0afcca38b97b057564d0e64bc4e30a5030cfe7c3f08c9ff6a3b499a0aac9.
Extraction method version: source-anchored-qualitative-context/v1.
Field locators: applicability.population → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalIntervention → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.experimentalInterventionComponents → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.comparator → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.design → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.outcomeConstruct → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract; applicability.participantMetric → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, participant context; applicability.timepoint → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, reported study timing; reportedDirection → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, author-reported results; limitations → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text: PubMed abstract, author-reported results.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40082711&rettype=abstract&retmode=text. Source hash: sha256:f81a6b9f221c0f3b305ed5508a82a621c2c069ed93390fd4529727deae570e13. Locators: applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; limitations: PubMed abstract, author-reported results; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; limitations: PubMed abstract, author-reported results; applicability.population: PubMed abstract; applicability.experimentalIntervention: PubMed abstract; applicability.experimentalInterventionComponents: PubMed abstract; applicability.comparator: PubMed abstract; applicability.design: PubMed abstract; applicability.outcomeConstruct: PubMed abstract; applicability.participantMetric: PubMed abstract, participant context; applicability.timepoint: PubMed abstract, reported study timing; reportedDirection: PubMed abstract, author-reported results; limitations: PubMed abstract, author-reported results; applicability.timepoint: PubMed abstract, reported study timing.
Canonical paper: /studies/40082711. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 40128734 · finding version 3 · paper version 4
plasma nitrateAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
plasma nitrate
Stable finding ID: finding:examine2025:40128734:1. Finding version: 3. Revision: finding:examine2025:40128734:1:v3. Content hash: sha256:8026db06431d4569cc55769dd4f1bea038a43624bb2c346c0e353a77f2826560.
Paper version: 4. Paper content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported WMD 32.7 µmol/L; 95% CI 26.1 to 39.4.
Systematic review / meta-analysis: 75 RCTs, 1823 participants. Per 1 mmol increase in dietary nitrate. Source window: acute.
Authors-reported finding: Authors reported WMD 32.7 µmol/L; 95% CI 26.1 to 39.4..
Each record retains its source-reported context and uncertainty.
Reported limitation: Authors-reported systematic-review estimate; no platform synthesis.
Finding revision: finding:examine2025:40128734:1:v3.
Finding version: 3.
Finding content hash: sha256:8026db06431d4569cc55769dd4f1bea038a43624bb2c346c0e353a77f2826560.
Paper version: 4.
Paper version content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
Source content hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: reviewScope → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2206-2257; doseIncrement → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2272-2335; estimate → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2337-2467.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text. Source hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d. Locators: reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2337-2467; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2337-2467; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2337-2467; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3.
Canonical paper: /studies/40128734. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 40128734 · finding version 3 · paper version 4
plasma nitrateAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
plasma nitrate
Stable finding ID: finding:examine2025:40128734:2. Finding version: 3. Revision: finding:examine2025:40128734:2:v3. Content hash: sha256:6af597b917ab31c5392314906c2a9e4e2ceef349251ec12439dd6f49bb2f666d.
Paper version: 4. Paper content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported WMD 19.6 µmol/L; 95% CI 9.95 to 29.3.
Systematic review / meta-analysis: 75 RCTs, 1823 participants. Per 1 mmol increase in dietary nitrate. Source window: chronic-term.
Authors-reported finding: Authors reported WMD 19.6 µmol/L; 95% CI 9.95 to 29.3..
Each record retains its source-reported context and uncertainty.
Reported limitation: Authors-reported systematic-review estimate; no platform synthesis.
Finding revision: finding:examine2025:40128734:2:v3.
Finding version: 3.
Finding content hash: sha256:6af597b917ab31c5392314906c2a9e4e2ceef349251ec12439dd6f49bb2f666d.
Paper version: 4.
Paper version content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
Source content hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: reviewScope → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2206-2257; doseIncrement → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2272-2335; estimate → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2337-2467.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text. Source hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d. Locators: reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2337-2467; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2337-2467; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2337-2467; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3.
Canonical paper: /studies/40128734. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 40128734 · finding version 3 · paper version 4
systolic blood pressureAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
systolic blood pressure
Stable finding ID: finding:examine2025:40128734:3. Finding version: 3. Revision: finding:examine2025:40128734:3:v3. Content hash: sha256:410c2a0cd668206a62a37d164d0a3907acd7735267752a7f8acd6f317b1a1f2c.
Paper version: 4. Paper content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported WMD -0.28 mmHg; 95% CI -0.4 to -0.17.
Systematic review / meta-analysis: 75 RCTs, 1823 participants. Per 1 mmol increase in dietary nitrate. Source window: acute.
Authors-reported finding: Authors reported WMD -0.28 mmHg; 95% CI -0.4 to -0.17..
Each record retains its source-reported context and uncertainty.
Reported limitation: Authors-reported systematic-review estimate; no platform synthesis.
Finding revision: finding:examine2025:40128734:3:v3.
Finding version: 3.
Finding content hash: sha256:410c2a0cd668206a62a37d164d0a3907acd7735267752a7f8acd6f317b1a1f2c.
Paper version: 4.
Paper version content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
Source content hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: reviewScope → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2206-2257; doseIncrement → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2272-2335; estimate → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2468-2717.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text. Source hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d. Locators: reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2468-2717; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2468-2717; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2468-2717; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3.
Canonical paper: /studies/40128734. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
PMID 40128734 · finding version 3 · paper version 4
systolic blood pressureAI-extracted — pending human review · Source record, not a recommendationOpen studied context and limitations before interpreting.Open complete studied context and source
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
systolic blood pressure
Stable finding ID: finding:examine2025:40128734:4. Finding version: 3. Revision: finding:examine2025:40128734:4:v3. Content hash: sha256:2f9cf78d29551932ab9d3c37f816ca74cd93cfac8384e621f5aa92d5b6c46471.
Paper version: 4. Paper content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
AI-extracted — pending human review
Source-authored record; platform synthesis is not enabled for this record.
Publication status: published.
Authors reported WMD -0.24 mmHg; 95% CI -0.4 to -0.07.
Systematic review / meta-analysis: 75 RCTs, 1823 participants. Per 1 mmol increase in dietary nitrate. Source window: short-term.
Authors-reported finding: Authors reported WMD -0.24 mmHg; 95% CI -0.4 to -0.07..
Each record retains its source-reported context and uncertainty.
Reported limitation: Authors-reported systematic-review estimate; no platform synthesis.
Finding revision: finding:examine2025:40128734:4:v3.
Finding version: 3.
Finding content hash: sha256:2f9cf78d29551932ab9d3c37f816ca74cd93cfac8384e621f5aa92d5b6c46471.
Paper version: 4.
Paper version content hash: sha256:51b2b58760155eaafbb6f0e20245aa48ecc62d8b60cfeecb7a6a68e2327319c5.
Source content hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d.
Extraction policy: context164-source-topic-policy:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction policy hash: sha256:d2c863b8d9f94acf3a7378bfa6e49a23bd72eea4408a689b542d3f7244fd7bfb.
Extraction method version: source-reported-records/v1.
Field locators: reviewScope → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2206-2257; doseIncrement → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2272-2335; estimate → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text: abstract:2468-2717.
Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=40128734&rettype=abstract&retmode=text. Source hash: sha256:9fa9c22cf9d2039b4169ea503159726df670555b7e72ec39efcf0599913e0b5d. Locators: reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2468-2717; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2468-2717; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3; reviewScope: abstract:2206-2257; doseIncrement: abstract:2272-2335; estimate: abstract:2468-2717; sourceTopic.typedRole: Abstract, source context clause 1; sourceTopic.typedRole: Abstract, source context clause 2; sourceTopic.typedRole: Abstract, source context clause 3.
Canonical paper: /studies/40128734. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.